Clinical trial NCT02324205: Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography (ADAPT)
Official title: Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography (ADAPT Trial) ADAPT-BX: Recruitment Plan for Initially Asymptomatic Women Referred for Breast Biopsy
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: NA
Conditions: Breast Cancer
Tumors, Breast
Lead sponsor: GE Healthcare
Sponsor class: INDUSTRY
First posted: 2014-12-24
Enrollment: 196
Sex: FEMALE
Minimum age (years): 30
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: All participants underwent 2D breast imaging with Full-field digital mammography (FFDM) and by 3D breast imaging with Digital Breast Tomosynthesis (DBT).
Primary purpose: DIAGNOSTIC

Brief summary: The aim of this recruitment plan (ADAPT-BX) is to collect image and technical data on both digital breast tomosynthesis (DBT) and full-field digital mammography (FFDM), along with other subject data including histology results from biopsy specimen examination and cancer classification data from initially asymptomatic women referred for biopsy after recall from screening and diagnostic work-up. These data will be included in a subsequent and prospectively planned pooled analysis described in a separate protocol (ADAPT-BIE) examining superiority of DBT to FFDM for breast cancer diagnosis and other clinical performance measures.

Detailed description: ADAPT program consists of 2 recruitment plans (ADAPT-SCR and ADAPT-BX) followed by an off-line read of the images and data collected (ADAPT-BIE). This study involves the comparison of two devices that can identify abnormalities in routine breast screening and diagnostic mammography. Mammography is usually done with full-field digital mammography (FFDM), which takes flat, two-dimensional X-ray images of the breast. Doctors use the two-dimensional images to look for cancers and other abnormal tissue. The purpose of this study is to learn more about the accuracy of full-field digital mammography devices and a new mammography device called digital breast tomosynthesis (DBT). DBT is similar to full-field digital mammography, but can also move around the breast to get X-ray images from different angles, which provides a three-dimensional view that doctors can use to look for cancers and abnormal tissue. Subjects will be recruited from an initially asymptomatic population that have been referred for clinically indicated breast biopsy based on suspicious breast imaging results. Subjects will undergo a DBT mammogram prior to biopsy. If FFDM was not performed within 30 days, subjects will also undergo FFDM prior to biopsy. Results of biopsy(ies) and histopathology, including lesion characteristics, will be recorded and considered as truth if positive for cancer status. Subjects with negative or benign histological findings will be followed for approximately one year (10-16 months) by FFDM and any additional standard of care practice.

Eligibility criteria: Inclusion Criteria:

* Women aged 30 years or older (≥30 years old);
* Initially asymptomatic women that underwent routine screening FFDM, breast ultrasound (U/S), breast magnetic resonance imaging (MRI) and/or DBT, followed by diagnostic work-up showing one of more abnormalities and referred for breast biopsy within of 30 days before study entry;
* Are able and willing to comply with study procedures;
* Have signed and dated the informed consent form;
* Documented as non-pregnant based on the investigator's medical judgment and in consideration of local clinical practice standards for evidence of non-pregnancy.

Exclusion Criteria:

* Have been previously included in this study;
* Have undergone diagnostic or surgical intervention(s) or procedure(s) on either breast, including mastectomy and cytopunction, before study-related imaging;
* Have breasts too large to be adequately positioned on 24 x 31 centimeter (cm) FFDM digital receptor without anatomical cut off during a DBT examination (or FFDM, if required);
* Have participated in (within the prior 30 days), another trial of an investigational product expected to interfere with study procedures or outcomes;
* Have breast implant(s);
* Have reconstructed breast(s).

Primary outcomes:
measure: Number of Participants With DBT, FFDM and Biopsy Specimens Collected.
timeFrame: Approximately 8 weeks
Secondary outcomes:
measure: Lesion Type Observed by FFDM Imaging
timeFrame: Approximately 8 weeks
measure: Lesion Type Observed by DBT Imaging
timeFrame: Approximately 8 weeks
measure: Maximum Lesion Dimension as Observed by FFDM
timeFrame: Approximately 8 weeks
measure: Maximum Lesion Dimension as Observed by DBT
timeFrame: Approximately 8 weeks
measure: Biopsy Finding of Lesions Per Subject.
timeFrame: Approximately 8 weeks
Other outcomes:
measure: Safety - Device Related Malfunctions
timeFrame: less than 16 months
Locations:
city: Boca Raton
country: United States
facility: Boca Raton Regional Hospital Christine E. Lynn Women's Health and Wellness Institute
state: Florida
city: Voorhees
country: United States
facility: Cooper Health - Cooper Breast Imaging Centers
state: New Jersey
city: Villejuif
country: France
facility: Gustave Roussy
Study officials:
affiliation: Gustave Roussy, Cancer Campus, Grand Paris
name: Corinne Balleyguier, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Cooper Health
name: Lydia Liao, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Boca Raton Regional Hospital
name: Kathy Schilling, MD
role: PRINCIPAL_INVESTIGATOR
References: